James Christopher Edgemond | United Therapeutics Corp. |
Martine A. Rothblatt | United Therapeutics Corp. |
Michael Benkowitz | United Therapeutics Corp. |
Chris Shibutani | Cowen & Co. LLC |
Terence Flynn | Goldman Sachs & Co. LLC |
Liana Moussatos | Wedbush Securities, Inc. |
Good morning and welcome to the United Therapeutics Corporation Third Quarter 2018 Earnings call. My name is Shelby, and I will be your conference operator today. All participants are in a listen-only mode until the question-and-answer session portion of this earnings call. I will now turn the conference call over to James Edgemond, Chief Financial Officer of United Therapeutics. Sir, you may begin.